1. Tse JY, Wong JH, Lo KW, Poon WS, Huang DP, Ng HK. Molecular genetic analysis of the von Hippel–Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol. 1997;107(4):459–66. https://doi.org/10.1093/ajcp/107.4.459
2. Latif F, Tory K, Gnarra J, Yao M, Duh F, Orcutt ML, et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science. 1993;260 (5112):1317–20. https//doi.org/10.1126/science.8493574
3. Takayanagi S, Mukasa A, Tanaka S, Nomura M, Omata M, Yanagisawa S, et al. Differences in genetic and epigenetic alterations between von Hippel–Lindau disease-related and sporadic hemangioblastomas of the central nervous system. Neuro Oncol. 2017;19(9):1228–36. https://doi.org/10.1093/neuonc/nox034
4. Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL–elongin C–elongin B complex: Implications for VHL tumor suppressor function. Science. 1999;284(5413):455–61. https://doi.org/10.1126/science.284.5413.455
5. Maxwell P, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The von Hippel–Lindau gene product is necessary for oxgyen-dependent proteolysis of hypoxia-inducible factor-α subunits. Nature. 1999;399(6733):271–5. https://doi.org/10.1038/20459
6. Flamme I, Krieg M, Plate KH. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol. 1998;153(1):25–9. https://doi.org/10.1016/s0002-9440(10)65541-1
7. Trimble M, Caro J, Talalla A, Brain M. Secondary erythrocytosis due to a cerebellar hemangioblastoma: Demonstration of erythropoietin mRNA in the tumor. Blood. 1991;78(3):599–601. https://doi.org/10.1182/blood.V78.3.599.599
8. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA. 1996;93:10595–9. https://doi.org/10.1073/pnas.93.20.10595
9. Krieg M, Marti HH, Plate KH. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel–Lindau tumor suppressor gene loss of function. Blood. 1998;92(9):3388–93.https://doi.org/10.1182/blood.V92.9.3388
10. Feldman MJ, Sizdahkhani S, Edwards NA, Merrill MJ, Ray-Chaudhury A, Zhuang Z, et al. Loss of quiescence in von Hippel–Lindau hemangioblastomas is associated with erythropoietin signaling. Sci Rep. 2016;6:35486. https://doi.org/10.1038/srep3 5486
11. Kanno H, Yoshizumi T, Shinonaga M, Kubo A, Murata H, Yao M. Role of VHL-JAK-STAT signaling pathway in central nervous system hemangioblastoma associated with von Hippel–Lindau disease. J Neurooncol. 2020;148(1):29–38. https://doi.org/10.1007/s11060-020-03506-8
12. Yue X, Zhang Z, Liang X, Gao L, Zhang X, Zhao D, Liu X, Ma H, Guo M, Spear BT, Gong Y, Ma C. Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E. Gastroenterology. 2012;142(7):1559–70.e2. https://doi.org/10.1053/j.gastro.2012.02.049
13. Nagel S, Schneider B, Meyer C, Kaufmann M, Drexler HG, Macleod RA. Transcriptional deregulation of homeobox gene ZHX2 in Hodgkin lymphoma. Leuk Res. 2012;36(5):646–55. https://doi.org/10.1016/j.leukres.2011.10.019
14. Kwon RJ, Kim YH, Jeong DC, Han ME, Kim JY, Liu L, et al. Expression and prognostic significance of zinc fingers and homeoboxes family members in renal cell carcinoma. PLoS One. 2017;12(2):e0171036. https://doi.org/10.1371/journal.pone.0171036
15. Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018;361(6399):290–5. https://doi.org/10.1126/science.aap8411
16. Yoshida M, Ashida K, Kondo K, Kobayashi H, Kanno H, Shinohara N, et al. Shitara N, Kishida T, Kawakami S, Baba M, Yamamoto I, Hosaka M, Shuin T, Yao M Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: An extended study of 77 families. Jpn J Cancer Res 2000; 91 (2):204–212. https://doi.org/10.1111/j.1349-7006.2000.tb00933.x
17. Hattori K, Teranishi J, Stolle C, Yoshida M, Kondo K, Kishida T, et al. Detection of germline deletions using real-time quantitative polymerase chain reaction in Japanese patients with von Hippel-Lindau disease. Cancer Sci. 2006;97(5):400–5. https://doi.org/10.1111/j.1349-7006.2006.00193.x
18. Kanno H, Kubo A, Yoshizumi T, Mikami T, Maegawa J. Isolation of multipotent nestin-expressing stem cells　derived from the epidermis of elderly humans and TAT-VHL peptide-mediated neuronal differentiation of these cells. Int J Mol Sci. 2013;14(5):9604–17. https://doi.org/ 10.3390/ijms14059604
19. Park DM, Zhuang Z, Chen L, Szerlip N, Maric I, Li J, Sohn T, et al. von Hippel–Lindau disease associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med. 2007;4(2):e60. https://doi.org/10.1371/journal.pmed.0040060
20. Takada S, Hojo M, Takebe N, Tanigaki K, Miyamoto S. Stromal cells of hemangioblastomas exhibit mesenchymal stem cell-derived vascular progenitor cell properties. Brain Tumor Pathol. 2018;35(4):193–201. https://doi.org/10.1007/s10014-018-0323-2
21. Li M, Song J, Pytel P. Expression of HIF-1 regulated proteins vascular endothelial growth factor, carbonic anhydrase IX and hypoxia inducible gene 2 in hemangioblastomas. Folia Neuropathol. 2014;52(3):234–42. https://doi.org/10.5114/fn.2014.45564
22. Mukherjee T, Kim WS, Mandal L, Banerjee U. Interaction between Notch and Hif-alpha in development and survival of drosophila blood cells. Science. 2011;332(6034):1210–3. https://doi.org/10.1126/scien ce.11996 43
23. Vihanto MM, Plock J, Erni D, Frey BM, Frey FJ, Huynh-Do U. Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin. FASEB J. 2005;19(12):1689–91. https://doi.org/10.1096/fj.04-3647fje
24. Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA, et al. Stromal cell-derived factor-1A and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: Von Hippel–Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 2005;65(14):6178–88. https://doi.org/10.1158/0008-5472.CAN-04-4406
25. Lappin TR, Lee FS. Update on mutations in the HIF: EPO pathway and their role in erythrocytosis. Blood Rev. 2019;37:100590. https://doi.org/10.1016/j.blre.2019.100590
26. Kaelin WG Jr. The VHL tumor suppressor gene: Insights into oxygen sensing and cancer. Trans Am Clin Climatol Assoc. 2017;128:298–307.
27. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8(11):865–73. https://doi.org/10.1038/nrc250223
28. Kanno H, Sato H, Yokoyama TA, Yoshizumi T, Yamada S. The VHL tumor suppressor protein regulates tumorigenicity of U87-derived glioma stem-like cells by inhibiting the JAK/STAT signaling pathway. Int J Oncol. 2013;42(3):881–6. https://doi.org/10.3892/ijo.2013.1773
29. Pierscianek D, Wolf S, Keyvani K, El Hindy N, Stein KP, Sandalcioglu IE, et al. Study of angiogenic signaling pathways in hemangioblastoma. Neuropathology. 2017;37(1):3–11. https://doi.org/10.1111/neup.12316
30. Tarade D, Ohh M. The HIF and other quandaries in VHL disease. Oncogene. 2018;37(2):139–47. https://doi.org/10.1038/onc.2017.338
31. Dai H, Wang C, Yu Z, He D, Yu K, Liu Y, et al. MiR-17 regulates prostate cancer cell proliferation and apoptosis through inhibiting JAK-STAT3 signaling pathway. Cancer Biother Radiopharm. 2018;33(3):103–9. https://doi.org/10.1089/cbr.2017.2386
32. Dolatabadi S, Jonasson E, Lindén M, Fereydouni B, Bäcksten K, Nilsson M, et al. JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma. Int J Cancer. 2019;145:435–49. https://doi.org/10.1002/ijc.32123
33. Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–84. https://doi.org/10.1038/ni.3691
34. Xu CH, Liu Y, Xiao LM, Chen LK, Zheng SY, Zeng EM, et al. Silencing microRNA-221/222 cluster suppresses glioblastoma angiogenesis by suppressor of cytokine signaling-3-dependent JAK/STAT pathway. J Cell Physiol. 2019;234(12):22272–84. https://doi.org/10.1002/jcp.28794
35. Zhang Y, Wang D, Xu J, Wang Y, Ma F, Li Z, et al. Stat3 activation is critical for pluripotency maintenance. J Cell Physiol. 2019;234(2):1044–51. https://doi.org/10.1002/jcp.27241
36. Fang W, Liao C, Shi R, Simon JM, Ptacek TS, Zurlo G, et al. ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer. Elife. 2021;10:e70412. https://doi.org/10.7554/eLife.70412